Navigation Links
New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer
Date:9/22/2009

KVISTGAARD, Denmark, September 22 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (OMX: BAVA) yesterday presented further detailed PROSTVAC(TM) data at the European Cancer Organisation (ECCO), ECCO 15 - 34th ESMO Congress in Berlin, Germany.

Further data from a Phase II double-blind, prospective randomized placebo-controlled study of 125 patients with metastatic prostate cancer was presented by Dr. Wayne Godfrey, Senior Medical Director, BN ImmunoTherapeutics.

The headline data as previously reported showed that patients in the PROSTVAC(TM) group had a significantly longer median overall survival by 8.5 months compared to the control group. The hazard ratio estimate for overall survival from the study is 0.56 (95% CI 0.37-0.85). The statistical significance in the final data set is (p=0.006). PROSTVAC(TM) also demonstrated a very favourable safety and tolerability profile.

A new statistical analysis of the data set showed that patients receiving PROSTVAC(TM) benefitted from the treatment regardless of their general condition or their median predicted survival, determined by the Halabi score. Similarly, when grouped by a number of relevant parameters, e.g. PSA level, PROSTVAC(TM) patients benefitted from treatment as compared to the control group. This data indicates that PROSTVAC(TM) is universally applicable to a wide range of prostate cancer patients. This confirms PROSTVAC(TM)'s potential to address a significant medical need and market opportunity. Furthermore, it will be useful in further defining the patient population for the pivotal phase III program.

An abstract from Dr. Godfrey's presentation is now available online at http://ex2.excerptamedica.com/CIW-09ecco/

Abstract no. O-7002.

Title: "Further analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC)"

As part of Bavarian Nordic's continued communication strategy on PROSTVAC(TM), the company will participate in the 16th Annual Prostate Cancer Foundation Scientific Retreat on September 24-26 at Lake Tahoe, Nevada, where a PROSTVAC(TM) poster has been accepted for presentation.

Anders Hedegaard, President & CEO of Bavarian Nordic said: "As we continue to analyse our PROSTVAC(TM) data, we gain new insight in the positive features of the vaccine and important information to facilitate the future clinical development of PROSTVAC(TM). With today's presentation at the ECCO congress along with our recent presentation at ASCO and other cancer congresses, we continue to broaden the awareness of PROSTVAC(TM) among leading cancer experts."

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline is focused in the three areas; biodefence, cancer and infectious diseases, and includes seven development programmes. Two programmes are ready for Phase III: IMVAMUNE(R), a third-generation smallpox vaccine is being developed under a contract with the US government, and PROSTVAC(TM), a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit http://www.bavarian-nordic.com


'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
2. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
3. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
4. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
5. Principle of Recursive Genome Function Supersedes Dogmas; By Andras Pellionisz, Online Ahead of Print; (Scientific Visionary Vindicated)
6. U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis
7. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
8. Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
9. New study indicates smallpox vaccination effective for decades
10. New study indicates smallpox vaccination effective for decades
11. Surveyed Experts Indicate That Byetta LAR and Victoza Have Advantages Over Actos in the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... Foresight Institute , a ... winners for the 2015 Foresight Institute Feynman Prizes. , These prestigious prizes, ... one for experiment and the other for theory in nanotechnology. Prof. Markus J. ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, ... new way to treat the disease. Surviving Mesothelioma has just posted an article on ... several Korean institutions based their mesothelioma study on the fact the Manumycin A, a ...
(Date:5/19/2016)... 19, 2016 There is no ... given the relentless pressures in pricing and lack in ... investors circle though - numerous opportunities are up for ... session, ActiveWallSt.com,s presents four names in this sector: Portola ... Inc. (NASDAQ: VTAE ), Anthera Pharmaceuticals Inc. ...
(Date:5/18/2016)... ... ... Tech Coast Angels (TCA) today announced that the Angel Capital Association ... Summit last week in Philadelphia. , The award recognizes the single-most ingenious ... is the highest honor available for an early-stage company to receive from the Angel ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):